Page last updated: 2024-10-27

gabapentin and Acute Lymphoid Leukemia

gabapentin has been researched along with Acute Lymphoid Leukemia in 3 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Children with acute lymphoblastic leukemia (ALL) often experience treatment-related neurocognitive deficits and significant pain."3.11Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia. ( Alberts, NM; Anghelescu, DA; Conklin, HM; Jacola, LM; Krull, KR; Partanen, M; Pui, CH, 2022)
" Only the risk classification of acute lymphoblastic leukemia was significantly associated with the daily morphine dosage (P = ."2.94Prospective randomized trial of interventions for vincristine-related neuropathic pain. ( Anghelescu, DL; Cheng, C; Jeha, S; Pauley, J; Pei, D; Pui, CH; Sandlund, JT; Tesney, JM; Trujillo, L; Wright, BB, 2020)
"Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life."1.37Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. ( Anghelescu, DL; Cheng, C; Faughnan, LG; Hankins, G; Hinds, PS; Jeha, S; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Sandlund, JT, 2011)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Partanen, M1
Alberts, NM1
Conklin, HM1
Krull, KR1
Pui, CH3
Anghelescu, DA1
Jacola, LM1
Anghelescu, DL2
Tesney, JM1
Jeha, S2
Wright, BB1
Trujillo, L1
Sandlund, JT2
Pauley, J1
Cheng, C2
Pei, D2
Faughnan, LG1
Relling, MV1
Hinds, PS1
Hankins, G1
Pauley, JL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111]Phase 3501 participants (Actual)Interventional2000-07-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion

InterventionPercent change (Mean)
4 hr-44
24 hr-50

Continuous Complete Remission Since Week 56 Therapy.

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years

InterventionPercentage of participants (Number)
Patients With High Risk of CNS Relapse92.2

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)

Interventionpmol/1,000,000,000 cells (Mean)
4 hr1688
24 hr2521

Overall Event-free Survival (EFS)

EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years

InterventionPercentage of Participants (Number)
Total Therapy87.3

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy341.3447.9

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy41.2110.7

Minimal Residual Disease (MRD)

Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)

Interventionparticipants (Number)
Negative <0.01%Positive >= 0.01%
Total Therapy390102

Trials

2 trials available for gabapentin and Acute Lymphoid Leukemia

ArticleYear
Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia.
    Pain, 2022, 06-01, Volume: 163, Issue:6

    Topics: Analgesics, Opioid; Child; Female; Gabapentin; Humans; Male; Neuralgia; Neuropsychological Tests; Pr

2022
Prospective randomized trial of interventions for vincristine-related neuropathic pain.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:9

    Topics: Adolescent; Analgesics; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Child; Child, Prescho

2020

Other Studies

1 other study available for gabapentin and Acute Lymphoid Leukemia

ArticleYear
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
    Pediatric blood & cancer, 2011, Dec-15, Volume: 57, Issue:7

    Topics: Adolescent; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Child; Child, Preschool;

2011